You are here

Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients

Last updated on April 11, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Depressive Syndrome, Anxiety
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
60+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients older than 60 years

- Depressive syndrome with associated anxiety symptoms, according to a symptoms
intensity HAM-D17³14

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Participation in other studies in the last 3 months before the start of the study

- Known hypersensibility to venlafaxine

- Clinically significant abnormalities according to the venlafaxine labeling

NCT00247429
Pfizer
Completed
Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Depressive Syndrome, Anxiety
NCT00247429
All Genders
Pain, Depression, Anxiety Disorder
NCT00241397
All Genders
18+
Years
Multiple Sites
Major Depressive Disorder
NCT02548949
All Genders
19+
Years
Multiple Sites
Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients
Vandral Retard (Venlafaxine Extended Release) in Depressive Syndrome With Anxiety and Painful Symptoms in Elderly Patients. Observational Study in Primary Care
In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome. We will also study secondarily its effects on anxiety, somatic and painful symptoms of depression.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   None Retained
Description:
No specimen retained
Non-Probability Sample
Primary care centers
  • Depressive Syndrome
  • Anxiety
Not Provided
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
59
October 2005
October 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients older than 60 years
  • Depressive syndrome with associated anxiety symptoms, according to a symptoms intensity HAM-D17³14

Exclusion Criteria:

  • Participation in other studies in the last 3 months before the start of the study
  • Known hypersensibility to venlafaxine
  • Clinically significant abnormalities according to the venlafaxine labeling
Sexes Eligible for Study: All
60 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00247429
101356
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Principal Investigator: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
August 2009

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now